- Mendel.ai is an AI-powered platform that revolutionizes clinical data workflows by enabling physician-level cognition and streamlining the clinical trial process, particularly in oncology research.
- In March 2026, Mendel raised $35 million in a Series B funding round led by Base10 Partners, with participation from PayPal Ventures, to enhance its AI capabilities and expand its enterprise spend management solutions.
- Mendel's software has been recognized by industry leaders, including a Senior Director of Bioinformatics at a top 50 life science company, for its ability to analyze large clinical data sets efficiently and effectively.
- The ideal buyer for Mendel.ai includes healthcare organizations and clinical research institutions looking to automate and optimize their clinical trial processes, addressing the pain points of data management and analysis in oncology research.
Mendel.ai's workforce is organized into eight departments, with a notable concentration in Information Technology, which employs nine individuals. The Operations and Other departments follow, with two and nine employees, respectively. The balance across departments indicates a lean structure, particularly in specialized areas such as Finance, Marketing, Engineering, and Human Resources, each staffed by one employee. This distribution reflects a focus on core technology functions while maintaining essential operational support.
The company's workforce is primarily based in two locations: San Jose, CA, with two employees, and Burlingame, CA, with one employee. The 'Other' category accounts for a significant portion of the workforce, totaling 22 individuals, indicating a distributed or remote working pattern. This geographic distribution suggests a flexible operational model, although the concentration in California highlights the company's regional focus.
